Section 232 Pharma Tariffs: CBP Guidance on Proclamation 11020

CBP releases implementation guidance for Section 232 pharmaceutical tariffs

On July 30, 2026, U.S. Customs and Border Protection published CSMS #69395344, providing implementation guidance for Presidential Proclamation 11020, signed April 2, 2026. That proclamation imposes additional Section 232 duties on imports of certain patented pharmaceuticals and their ingredients, including active pharmaceutical ingredients (APIs) and key starting materials used to manufacture patented drugs.

This is a significant duty-exposure development for pharmaceutical importers, contract manufacturers, and the customs brokers and trade attorneys who serve them. Section 232 actions carry additional duties layered on top of normal column 1 rates and any existing Section 301 exposure, so affected parties need to confirm which HTS classifications fall under the proclamation's scope and whether any exclusion or mitigation pathways apply.

CBP's CSMS message is the primary operational document for understanding how the agency expects entries to be filed. Importers should review it carefully to identify which chapter 99 special provision codes apply to their products and to ensure their entry data reflects the correct duty treatment from the date the proclamation took effect.

ACE quota processing issue affecting chapter 99 HTS codes

Also on July 30, CBP issued CSMS #69395228 alerting the trade community to an active quota processing issue in ACE. The problem is specifically tied to certain chapter 99 harmonized tariff schedule codes. CBP stated it is investigating the issue and will issue a follow-up message once a fix has been implemented.

Because chapter 99 codes are the mechanism through which Section 232, Section 301, and other special-measure duties are assessed, any processing error in that chapter can affect duty calculations, quota fill reporting, and entry acceptance. Importers and brokers with quota-sensitive shipments subject to chapter 99 overlays should monitor ACE closely and watch for the follow-up CSMS before assuming entries have processed correctly.

ACE production maintenance window: August 1 to 2, 2026

CBP also announced via CSMS #69391098 that ACE will undergo standard invasive production maintenance from 10:00 p.m. ET Saturday, August 1, 2026, to 4:00 a.m. ET Sunday, August 2, 2026. During this six-hour window, ACE production functionality may be unavailable or degraded. Brokers and filers with time-sensitive entries or quota filings should plan accordingly.

What importers should do

• Review CSMS #69395344 in full to determine whether your patented pharmaceutical or API imports fall within the scope of Proclamation 11020, and verify that the correct chapter 99 codes and additional duty rates are reflected in your entry filings.
• If you have active or pending quota entries using chapter 99 HTS codes, check ACE for any processing anomalies and hold off on relying on quota-fill confirmations until CBP publishes a resolution to the issue described in CSMS #69395228.
• Schedule any quota-sensitive or time-critical ACE filings before 10:00 p.m. ET on August 1 or after 4:00 a.m. ET on August 2 to avoid the maintenance window.
• Consult your classification and compliance records to assess whether any Section 232 exclusion pathways exist for your specific patented pharmaceutical products or ingredients.